Tirzepatide vs. the GLP-1 Field: What the Switching Data Actually Shows

Until recently, the question of how to move a patient from a pure GLP-1 receptor agonist — semaglutide, dulaglutide, liraglutide — onto tirzepatide, which hits both the GLP-1 and GIP receptors, was answered mostly by clinician instinct. The drugs are cousins, not twins. Tirzepatide's dual-agonist mechanism is meaningfully different, and there was no clean protocol for the handoff.

A 2024 retrospective case series out of a hospital pharmacy is one of the first published attempts to fill that gap. The authors followed 10 adults with type 2 diabetes who met internal criteria for switching from a GLP-1 RA to tirzepatide, and tracked A1C and weight at three and six months. The mean A1C change was −0.7% at 3 months and −1.4% at 6 months, with mean weight loss of 3.6 kg and 6 kg over the same windows. A third of the patients with six-month follow-up hit at least 10% body-weight reduction. Few adverse events were reported.

Read that paragraph again before you get excited. Ten patients. Retrospective. Open-label by definition. No control arm. The authors themselves frame it as hypothesis-generating — a signal that switching can be considered when A1C and weight goals aren't being met on a GLP-1 alone. That is a long way from a randomized trial telling you it's better.

Zoom out and the switching question is really a market question. Tirzepatide has become the dominant story in this class because the phase-3 program for type 2 diabetes and obesity put up numbers that older GLP-1s, on average, didn't match. As clinicians try to translate that into care, patients on dulaglutide or semaglutide are asking whether to move — and the case series above is, frankly, the only thing in the published record that even gestures at an answer for that specific transition.

Meanwhile, the back end of the GLP-1 market is doing something the supplement aisle has done for decades — fragmenting into branded and generic-equivalent options. That's where the second paper comes in.

In a multicenter, randomized, open-label, active-comparator phase-3 study, 440 Chinese adults with type 2 diabetes were randomized 1:1 to either LY05008 — a dulaglutide biosimilar — or the reference product dulaglutide (Trulicity), 1.5 mg subcutaneously once weekly for 24 weeks. The primary endpoint was change in HbA1c from baseline to week 24. The two arms landed essentially on top of each other: −1.44% for the biosimilar versus −1.41% for the reference product. Safety, pharmacokinetics, and immunogenicity were also assessed.

That's exactly what a biosimilar trial is supposed to show, and it's what every lifter who has ever sourced a generic version of a brand-name drug should pay attention to: when the regulatory machinery works, a well-run phase-3 study can demonstrate that a biosimilar performs in the same neighborhood as the originator. It does not mean every grey-market peptide labeled “dulaglutide” on the internet is the same molecule. It means one specific product, in one specific trial, met the bar.

If you're the kind of lifter who actually pulls up PubMed before changing your pre-workout, here's the honest framing. The switching evidence is a small, retrospective signal that tirzepatide can do additional work in patients who haven't reached their goals on an older GLP-1. The biosimilar evidence is a much more robust signal that the dulaglutide molecule, made by a different manufacturer to a regulated standard, can perform comparably to the originator over six months.

Neither of these is a green light for the gym-bro use case. Both studies were in people with type 2 diabetes, under clinical supervision, with structured monitoring of A1C, weight, and side effects. The relevant outcomes for a metabolically healthy 28-year-old chasing a leaner offseason — long-term lean-mass retention, training performance, recovery, endocrine effects over years — are not in these papers. They're not in most of the GLP-1 literature yet, full stop.

The class is moving fast. The data is moving slower. That gap is where hype lives, and where the people selling you something thrive. The smart move, as always, is to read the actual studies, talk to a clinician who knows your bloodwork, and let the evidence — not the algorithm — set the pace.